Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The audit has been concluded with no major observations
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The inspection concluded with zero Form 483 observations
Changhua site meets international regulatory standards for global medical applications
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The company received seven observations in the Form-483
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
